B+
Bull case
25%
Probability
Target price
$42.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
ZYME
ZymeworksBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull case rests on the August zanidatamab regulatory decision, potential milestone and royalty expansion, the planned Theravance closing, and additional partnered or wholly owned pipeline catalysts. The Q2 release also described a $322.5 million liquidity position and continued capital returns.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +13.3.
What can break
FDA delay, rejection, or restrictive labeling for zanidatamab could eliminate or defer the potential milestone and royalty uplift.
Momentum
84
Value
41
Sentiment
77
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $31.00 · Bull $42.00 · Bear $16.00Analysis 2026-08-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $41.75
Why
Momentum84 · Δ7d -2.0
Value41 · Δ7d 0.0
Sentiment77 · Δ7d +13.3
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +13.3.
Contradictions & invalidation
- • FDA delay, rejection, or restrictive labeling for zanidatamab could eliminate or defer the potential milestone and royalty uplift.
- • HERIZON-GEA-01 and other pipeline readouts may disappoint or be delayed.
- • The thesis remains event-driven: FDA approval, the acquisition closing, and clinical updates are not assured.
Catalyst clock
2026-08-25
FDA PDUFA decision for zanidatamab
Lead driver: Sentiment · See AI snapshot
Momentum
84
9% active weight
Current posture
7d trendFlat
Δ7d
-2.0
Δ21d
+56.2
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
77
62% active weight
Current posture
7d trendImproving
Δ7d
+13.3
Δ21d
-8.7
Why this grade
Composite grade B. Momentum 84.1 / Value 41.2 / Sentiment 76.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-08. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$31.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$16.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$1.81B
Beta
1.25
Shares Out
71.51M
P/E (TTM) · Derived
-23.5
P/S (TTM)
14.18
P/FCF (TTM) · Derived
-15.68
Rev YoY
-90.6%
EPS YoY
-2162.9%
Gross Margin
+75.6%
Op Margin
-419.0%
Net Debt
-$210.53M
Current Ratio
6.32
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data